Article
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.
Cancer discovery - 1 May 2014
Wagle Nikhil, Grabiner Brian C, Van Allen Eliezer M, Hodis Eran, Jacobus Susanna, Supko Jeffrey G, Stewart Michelle, Choueiri Toni K, Gandhi Leena, Cleary James M, Elfiky Aymen A, Taplin Mary Ellen, Stack Edward C, Signoretti Sabina, Loda Massimo, Shapiro Geoffrey I, Sabatini David M, Lander Eric S, Gabriel Stacey B, Kantoff Philip W, Garraway Levi A, Rosenberg Jonathan E
Abstract excerpt
Understanding the genetic mechanisms of sensitivity to targeted anticancer therapies may improve patient selection, response to therapy, and rational treatment designs. One approach to increase this understanding involves detailed studies of exceptional responders: rare patients with unexpected exquisite sensitivity or durable responses to therapy. We identified an exceptional responder in a phase I study of...
Read the complete abstract on PubMedTopics
- Aged
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma, Transitional Cell